mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us
Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for BRAF
Gene summary
Basic gene Info.Gene symbolBRAF
Gene nameB-Raf proto-oncogene, serine/threonine kinase
SynonymsB-RAF1|BRAF1|NS7|RAFB1
CytomapUCSC genome browser: 7q34
Type of geneprotein-coding
RefGenesNM_004333.4,
Description94 kDa B-raf proteinB-Raf proto-oncogene serine/threonine-protein kinase (p94)murine sarcoma viral (v-raf) oncogene homolog B1proto-oncogene B-Rafserine/threonine-protein kinase B-rafv-raf murine sarcoma viral oncogene homolog Bv-raf murine sarcoma
Modification date20141222
dbXrefs MIM : 164757
HGNC : HGNC
Ensembl : ENSG00000157764
HPRD : 01264
Vega : OTTHUMG00000157457
ProteinUniProt: P15056
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_BRAF
BioGPS: 673
PathwayNCI Pathway Interaction Database: BRAF
KEGG: BRAF
REACTOME: BRAF
Pathway Commons: BRAF
ContextiHOP: BRAF
ligand binding site mutation search in PubMed: BRAF
UCL Cancer Institute: BRAF
Assigned class in mutLBSgeneDBA: This gene has a literature evidence and it belongs to targetable_mutLBSgenes.
References showing study about ligand binding site mutation for BRAF.1. "Kondo T, Nakazawa T, Murata S, Kurebayashi J, Ezzat S, Asa SL, Katoh R. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol. 2007 Dec;38(12):1810-8. Epub 2007 Aug 21. PubMed PMID: 17714762. " 17714762
2. "Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014 Sep;24(9):1385-93. doi: 10.1089/thy.2014.0134. Epub 2014 Jul 15. PubMed PMID: 24955518; PubMed Central PMCID: PMC4148060." 24955518
3. "Tang HC, Chen YC. Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma. Int J Nanomedicine. 2015 Apr 23;10:3131-46. doi: 10.2147/IJN.S80150. eCollection 2015. PubMed PMID: 25960652; PubMed Central PMCID: PMC4412490. " 25960652

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID
GO:0006468protein phosphorylation17563371
GO:0033138positive regulation of peptidyl-serine phosphorylation19667065
GO:0043066negative regulation of apoptotic process19667065
GO:0070374positive regulation of ERK1 and ERK2 cascade22065586
GO:0071277cellular response to calcium ion18567582


Top
Ligand binding site mutations for BRAF
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
 : non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
A598V600ETHCA182
A598V600ESKCM85
A598V600ECOAD20
A598V600EGBM5
F468G469VLUAD4
D594D594NCOAD3
G466G466VLUAD3
G466G466ESKCM3
G464G464RCOAD2
F468,G466S467PCOAD2
F468G469ACOAD2
F583L584PCOAD2
N581N581SLUAD2
A598V600ELUAD2
F468G469ALUAD2
F468,G466S467LSKCM2
Y538,S536L537SBRCA1
G593G593CCOAD1
D594D594GCOAD1
F583F583SCOAD1
I463R462GCOAD1
L597L597PCOAD1
I592K591ECOAD1
I592V590ACOAD1
V471V471ACOAD1
I463I463VCOAD1
G466G466RCOAD1
G466G466VCOAD1
F468F468LCOAD1
F468G469ECOAD1
F595F595SCOAD1
G596G596DGBM1
D594D594NLUAD1
L514L514PLUAD1
D594D594HLUAD1
G466G466ALUAD1
F468G469RLUSC1
G466G466VLUSC1
G464G464VLUSC1
N581N581SOV1
N581N581TSKCM1
F468G469ASKCM1
D594D594NSKCM1
L597L597QSKCM1
F468G469RSKCM1
N581N581SSKCM1
F468G469ESKCM1
D594D594NSTAD1
I463R462KUCEC1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Clinical information for BRAF from My Cancer Genome.
The V600E mutation results in an amino acid substitution at position 600 in BRAF, from a valine (V) to a glutamic acid (E). This mutation occurs within the activation segment of the kinase domain (Figure 1). Approximately 80–90% of V600 BRAF mutations are V600E (COSMIC; Lovly et al. 2012; Rubinstein et al. 2010). Mutations at V600 result in increased kinase activity and are transforming in vitro. BRAF mutations are usually found in tumors with no driver mutations in NRAS, KIT, and other genes.BRAF V600E mutations are associated with increased sensitivity to BRAF inhibitors (Chapman et al. 2011; Falchook et al. 2012a; Flaherty et al. 2010; Flaherty et al. 2012a; Hauschild et al. 2012; Sosman et al. 2012).Patients whose tumors harbored V600E and V600K mutations showed better responses to the MEK inhibitor, trametinib, than to chemotherapy (dacarbazine or paclitaxel; Flaherty et al. 2012b); patients with V600E or V600K-mutated tumors also showed better responses to trametinib than patients with BRAF wild type tumors (Falchook et al. 2012b).The FDA has approved use of the combination therapy dabrafenib and trametinib for melanoma patients with V600E or V600K mutations based on an interim analysis of a phase III trial showing improved response rates and response duration compared to dabrafenib alone (FDA 2014; Long et al. 2014). Improved progression-free survival and response rates compared to dabrafenib monotherapy were observed in an earlier phase I/II trial, as well (Flaherty et al. 2012a).Patients with V600-mutated tumors and no prior BRAF inhibitors treated with combination vemurafenib and cobimetinib experienced improved response rate and progression-free survival compared to patients with V600-mutated tumors and recent progression on vemurafenib (Ribas et al. 2014). This study included patients with V600E and V600K mutations (Ribas et al. 2014).Lovly, C., W. Pao, J. Sosman. 2015. BRAF c.1799T>A (V600E) Mutation in Melanoma. My Cancer Genome https://www.mycancergenome.org/content/disease/melanoma/braf/54/ (Updated June 16).

Top
Protein structure related information for BRAF
Protein structure of wild type (WT) and mutant type (MT) of BRAF
Wild type BRAF
Mutant type BRAF

Free energy of binding of drugs to wild type and mutant tpye of BRAF
Gene symbolDrug nameFree energy of binding (kcal/mol) of wild typeFree energy of binding (kcal/mol) of mutant type
BRAFDabrafenib-10.1-9
BRAFRegorafenib-9.7-9.4
BRAFVemurafenib-9.7-11.8

Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
G466G466V0.27685229
G466G466E0.24351413
G466G466R0.17410586
F595F595S0.10990751
F468F468L0.064337218
F583L584P-1.8152841
L514L514P-1.693253
S536L537S-1.4571753
Y538L537S-1.4571753
V471V471A-1.4459912
F583F583S-1.4431249
I592V590A-1.3800203
L597L597Q-1.3503094
I463R462G-1.313254
D594D594G-1.2279984
L597L597P-1.1926655
G593G593C-1.1724717
I463R462K-1.1470357
D594D594N-1.1272623
D594D594H-1.1104892
G464G464R-1.0964551
G596G596D-1.061375
G464G464V-1.0253723
G466S467P-0.93947437
F468S467P-0.93947437
N581N581S-0.86678303
N581N581T-0.74975157
I592K591E-0.7439051
F468G469A-0.70038964
A598V600E-0.68886259
G466S467L-0.56490356
F468S467L-0.56490356
F468G469R-0.49648081
F468G469V-0.48817585
F468G469E-0.44113949
I463I463V-0.33562603
G466G466A-0.11982765
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for BRAF from PDB
PDB IDPDB titlePDB structure
3OG7B-Raf Kinase V600E oncogeic mutant in complex with PLX4032

Top
Differential gene expression and gene-gene network for BRAF
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types
BRAF_COAD_DE
BRAF_LUAD_DE
BRAF_THCA_DE

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of BRAF and the right PPI network was created from samples without mutations in the LBS of BRAF. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.

* In COAD

* In LUAD

* In THCA


Top

Top
Phenotype information for BRAF
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C0025202Melanoma688AlteredExpression, Biomarker, GeneticVariation
umls:C1527249Colorectal Cancer247Biomarker, GeneticVariation
umls:C0040136Thyroid Neoplasms97AlteredExpression, Biomarker, GeneticVariation
umls:C0009404Colorectal Neoplasms55Biomarker, GeneticVariation, PostTranslationalModification
umls:C0699790Colon Carcinoma47Biomarker, GeneticVariation
umls:C1275081Cardiofaciocutaneous syndrome26Biomarker, GeneticVariation
umls:C0017638Glioma23Biomarker, GeneticVariation
umls:C0007131Carcinoma, Non-Small-Cell Lung23Biomarker, GeneticVariation
umls:C0004114Astrocytoma16Biomarker, GeneticVariation
umls:C0684249Carcinoma of lung14Biomarker, GeneticVariation
umls:C0028326Noonan Syndrome8Biomarker, GeneticVariation
umls:C0152013Adenocarcinoma of lung8Biomarker, GeneticVariation
umls:C0587248Costello Syndrome5Biomarker
umls:C0024121Lung Neoplasms3Biomarker, GeneticVariation
umls:C0023903Liver Neoplasms3Biomarker, GeneticVariation
umls:C0002448Ameloblastoma3Biomarker, GeneticVariation
umls:C0206686Adrenocortical Carcinoma3Biomarker, GeneticVariation
umls:C0206754Neuroendocrine Tumors3Biomarker
umls:C0024694Mandibular Neoplasms2Biomarker, GeneticVariation
umls:C0022665Kidney Neoplasms2Biomarker
umls:C0024305Lymphoma, Non-Hodgkin1GeneticVariation
umls:C0010276Craniopharyngioma1Biomarker, GeneticVariation

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs
29000V600EPathogenicGermline;somaticMedGen:C0007131
SNOMED CT:254637007
MedGen:C0025202
SNOMED CT:2092003
MedGen:C0238463
OMIM:188550
Orphanet:ORPHA146
SNOMED CT:255029007
MedGen:C0699790
SNOMED CT:269533000
MedGen:C1266158
MedGen:CN221809
29006G466VPathogenicSomaticMedGen:C0007131
SNOMED CT:254637007
MedGen:C0152013
29009G469RPathogenicGermline;somaticMedGen:C0024305
OMIM:605027
Orphanet:ORPHA547
SNOMED CT:1929004
MedGen:CN166718
29010G469APathogenicSomaticMedGen:C0007131
SNOMED CT:254637007
MedGen:C0024305
OMIM:605027
Orphanet:ORPHA547
SNOMED CT:1929004
29011D594GPathogenicSomaticMedGen:C0007131
SNOMED CT:254637007
MedGen:C0024305
OMIM:605027
Orphanet:ORPHA547
SNOMED CT:1929004
29013G469EPathogenicGermline;unknownGeneReviews:NBK1186
MedGen:CN029449
OMIM:115150
Orphanet:ORPHA1340
MedGen:CN166718
48834G464VPathogenicSomatic;unknownMedGen:C0007131
SNOMED CT:254637007
MedGen:CN166718
53968G466RLikely pathogenicSomaticMedGen:C0007131
SNOMED CT:254637007
53970G469VPathogenicSomaticMedGen:C0007131
SNOMED CT:254637007
53980D594NLikely pathogenicSomaticMedGen:C0007131
SNOMED CT:254637007
174177N581SLikely pathogenicSomaticMedGen:C0007131
SNOMED CT:254637007
174179G469RLikely pathogenicSomaticMedGen:C0007131
SNOMED CT:254637007

Top
Pharmacological information for BRAF
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
Approved|investigationalDB00398SorafenibSmall molecule
InvestigationalDB05190XL281Small molecule
InvestigationalDB05238PLX4032Small molecule
ExperimentalDB06999N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamideSmall molecule
ExperimentalDB07000N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamideSmall molecule
ExperimentalDB08553(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oximeSmall molecule
ApprovedDB08881VemurafenibSmall molecule
ApprovedDB08896RegorafenibSmall molecule
ApprovedDB08912DabrafenibSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of BRAF go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
P06DABRAFENIBN-{3-[5-(2-AMINOPYRIMIDIN-4-YL)-2-TERT-BUTYL-1,3- THIAZOL-4-YL]-2-FLUOROPHENYL}-2,6- DIFLUOROBENZENESULFONAMIDE4xv2AG464 F468 V471 L514 F583 G593 D594 F595
P06DABRAFENIBN-{3-[5-(2-AMINOPYRIMIDIN-4-YL)-2-TERT-BUTYL-1,3- THIAZOL-4-YL]-2-FLUOROPHENYL}-2,6- DIFLUOROBENZENESULFONAMIDE4xv2BG464 G466 F468 V471 L514 F583 G593 D594 F595
7345-CHLORO-7-[(R)-FURAN-2-YL(PYRIDIN-2-YLAMINO)METHYL]QUINOLIN-8-OL4e26BI463 G464 S536 F583
215(1Z)-5-(2-{4-[2-(DIMETHYLAMINO)ETHOXY]PHENYL}-5-PYRIDIN-4-YL-1H-IMIDAZOL-4-YL)INDAN-1-ONE OXIME2fb8AI463 G464 V471 L514 F583 D594
SM5(1E)-5-(1-PIPERIDIN-4-YL-3-PYRIDIN-4-YL-1H-PYRAZOL-4-YL)-2,3-DIHYDRO-1H-INDEN-1-ONE OXIME3d4qAI463 G464 V471 L514 F583 D594
SM5(1E)-5-(1-PIPERIDIN-4-YL-3-PYRIDIN-4-YL-1H-PYRAZOL-4-YL)-2,3-DIHYDRO-1H-INDEN-1-ONE OXIME3d4qBI463 G464 V471 L514 F583 D594
FP43-(4-{[2-(PYRIMIDIN-2-YL)FURO[2,3-C]PYRIDIN-3-YL]AMINO}-1H-INDAZOL-3-YL)PROPAN-1-OL3priAI463 G466 V471 L514 N581 F583 D594
FP43-(4-{[2-(PYRIMIDIN-2-YL)FURO[2,3-C]PYRIDIN-3-YL]AMINO}-1H-INDAZOL-3-YL)PROPAN-1-OL3priBI463 G466 V471 N581 F583 D594
904N'-(3-{[5-(2-CYCLOPROPYLPYRIMIDIN-5-YL)-1H-PYRROLO[2,3- B]PYRIDIN-3-YL]CARBONYL}-2,4-DIFLUOROPHENYL)-N-ETHYL- N-METHYLSULFURIC DIAMIDE4xv1AI463 L514 D594 F595 G596
0WP3-{[3-(2-CYANOPROPAN-2-YL)BENZOYL]AMINO}-2,6-DIFLUORO- N-(3-METHOXY-2H-PYRAZOLO[3,4-B]PYRIDIN-5-YL)BENZAMIDE4g9cAI463 L514 F583 G593 D594 F595
0WP3-{[3-(2-CYANOPROPAN-2-YL)BENZOYL]AMINO}-2,6-DIFLUORO- N-(3-METHOXY-2H-PYRAZOLO[3,4-B]PYRIDIN-5-YL)BENZAMIDE4g9cBI463 L514 F583 G593 D594 F595
7345-CHLORO-7-[(R)-FURAN-2-YL(PYRIDIN-2-YLAMINO)METHYL]QUINOLIN-8-OL4e26AI463 L514 S536 F583
29L2-{4-[(1E)-1-(HYDROXYIMINO)-2,3-DIHYDRO-1H-INDEN-5-YL]- 3-(PYRIDIN-4-YL)-1H-PYRAZOL-1-YL}ETHANOL4mnfBI463 V471 F583
FOIMETHYL 3-{[(5S)-1-(HYDROXYAMINO)-5H-INDEN-5-YL]AMINO}FURO[2,3-C]PYRIDINE-2-CARBOXYLATE3ppjBI463 V471 F583 D594
FNI3-[(5-HYDROXYNAPHTHALEN-2-YL)AMINO]-N-(PYRIMIDIN-4-YL)FURO[2,3-C]PYRIDINE-2-CARBOXAMIDE3ppkAI463 V471 F583 D594
FNI3-[(5-HYDROXYNAPHTHALEN-2-YL)AMINO]-N-(PYRIMIDIN-4-YL)FURO[2,3-C]PYRIDINE-2-CARBOXAMIDE3ppkBI463 V471 F583 D594
SM6ETHYL 3-{[1-(HYDROXYAMINO)-2H-INDEN-5-YL]AMINO}THIENO[2,3-C]PYRIDINE-2-CARBOXYLATE3psbAI463 V471 F583 D594
SM6ETHYL 3-{[1-(HYDROXYAMINO)-2H-INDEN-5-YL]AMINO}THIENO[2,3-C]PYRIDINE-2-CARBOXYLATE3psbBI463 V471 F583 D594
2VXN-{2,4-DIFLUORO-3-[METHYL(3-METHYL-4-OXO-3,4- DIHYDROQUINAZOLIN-6-YL)AMINO]PHENYL}PROPANE-1- SULFONAMIDE4pp7BI463 V471 L514 D594 F595 G596
324N-{3-[(5-CHLORO-1H-PYRROLO[2,3-B]PYRIDIN-3-YL)CARBONYL]-2,4-DIFLUOROPHENYL}PROPANE-1-SULFONAMIDE3c4cBI463 V471 L514 F583 D594
FOIMETHYL 3-{[(5S)-1-(HYDROXYAMINO)-5H-INDEN-5-YL]AMINO}FURO[2,3-C]PYRIDINE-2-CARBOXYLATE3ppjAI463 V471 L514 F583 D594
FP32-CHLORO-5-{[2-(PYRIMIDIN-2-YL)FURO[2,3-C]PYRIDIN-3-YL]AMINO}PHENOL3prfBI463 V471 L514 F583 D594
SM76-[1-(PIPERIDIN-4-YL)-3-(PYRIDIN-4-YL)-1H-PYRAZOL-4-YL]INDENO[1,2-C]PYRAZOLE3psdAI463 V471 L514 F583 D594
SM76-[1-(PIPERIDIN-4-YL)-3-(PYRIDIN-4-YL)-1H-PYRAZOL-4-YL]INDENO[1,2-C]PYRAZOLE3psdBI463 V471 L514 F583 D594
324N-{3-[(5-CHLORO-1H-PYRROLO[2,3-B]PYRIDIN-3-YL)CARBONYL]-2,4-DIFLUOROPHENYL}PROPANE-1-SULFONAMIDE3c4cAI463 V471 L514 F583 D594 F595
325N-{2,4-DIFLUORO-3-[(5-PYRIDIN-3-YL-1H-PYRROLO[2,3-B]PYRIDIN-3-YL)CARBONYL]PHENYL}ETHANESULFONAMIDE4fk3AI463 V471 L514 F583 D594 F595 G596
FP32-CHLORO-5-{[2-(PYRIMIDIN-2-YL)FURO[2,3-C]PYRIDIN-3-YL]AMINO}PHENOL3prfAI463 V471 L514 F583 G593 D594
55J1-METHYL-5-({2-[5-(TRIFLUOROMETHYL)-1H-IMIDAZOL-2- YL]PYRIDIN-4-YL}OXY)-N-[4-(TRIFLUOROMETHYL)PHENYL]-1H- BENZIMIDAZOL-2-AMINE5ct7AI463 V471 L514 F583 I592 G593 D594 F595
55J1-METHYL-5-({2-[5-(TRIFLUOROMETHYL)-1H-IMIDAZOL-2- YL]PYRIDIN-4-YL}OXY)-N-[4-(TRIFLUOROMETHYL)PHENYL]-1H- BENZIMIDAZOL-2-AMINE5ct7BI463 V471 L514 F583 I592 G593 D594 F595
1OON-{3-[(5-CHLORO-1H-PYRROLO[2,3-B]PYRIDIN-3-YL) CARBONYL]-2,4-DIFLUOROPHENYL}-4-(TRIFLUOROMETHYL) BENZENESULFONAMIDE4xv9AI463 V471 L514 F583 I592 G593 D594 F595
B1E3-(2-CYANOPROPAN-2-YL)-N-{4-METHYL-3-[(3-METHYL-4-OXO- 3,4-DIHYDROQUINAZOLIN-6-YL)AMINO]PHENYL}BENZAMIDE4g9rBI463 V471 L514 G593 D594 F595
215(1Z)-5-(2-{4-[2-(DIMETHYLAMINO)ETHOXY]PHENYL}-5-PYRIDIN-4-YL-1H-IMIDAZOL-4-YL)INDAN-1-ONE OXIME2fb8BI463 V471 Y538 F583 D594
BR22,6-DIFLUORO-N-[(5S)-3-METHOXY-5H-PYRAZOLO[3,4-B]PYRIDIN-5-YL]-3-[(PHENYLSULFONYL)AMINO]BENZAMIDE3skcBL514 F583 D594 F595 G596
TV4N-(6-AMINO-5-BROMOPYRIDIN-3-YL)-2,6-DIFLUORO-3-[(PROPYLSULFONYL)AMINO]BENZAMIDE3tv4AL514 F583 D594 F595 G596
B0R2,6-DIFLUORO-N-(3-METHOXY-2H-PYRAZOLO[3,4-B]PYRIDIN-5-YL)-3-[(PROPYLSULFONYL)AMINO]BENZAMIDE3tv6AL514 F583 D594 F595 G596
RI9N-{2,4-DIFLUORO-3-[({6-[(2-HYDROXYETHYL) AMINO]PYRIMIDIN-4-YL}CARBAMOYL)AMINO]PHENYL}PROPANE-1- SULFONAMIDE4ehgBL514 F583 D594 F595 G596
B0R2,6-DIFLUORO-N-(3-METHOXY-2H-PYRAZOLO[3,4-B]PYRIDIN-5-YL)-3-[(PROPYLSULFONYL)AMINO]BENZAMIDE3tv6BL514 F583 D594 F595 G596 L597
B961-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA4jvgAL514 F583 G593 D594 F595
B961-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA4jvgDL514 F583 G593 D594 F595
0NF(2S)-N-[3-(2-AMINOPROPAN-2-YL)-5-(TRIFLUOROMETHYL)PHENYL]-7-[(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-4-YL)OXY]-1,2,3,4-TETRAHYDRONAPHTHALENE-2-CARBOXAMIDE3q96AL514 G593 D594 F595
BR22,6-DIFLUORO-N-[(5S)-3-METHOXY-5H-PYRAZOLO[3,4-B]PYRIDIN-5-YL]-3-[(PHENYLSULFONYL)AMINO]BENZAMIDE3skcAL514 G593 D594 F595
B1E3-(2-CYANOPROPAN-2-YL)-N-{4-METHYL-3-[(3-METHYL-4-OXO- 3,4-DIHYDROQUINAZOLIN-6-YL)AMINO]PHENYL}BENZAMIDE4g9rAL514 G593 D594 F595
DFS2,6-DIFLUORO-N-(1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-3- [(PROPYLSULFONYL)AMINO]BENZAMIDE4mbjBL514 G593 F595 G596
T1QN-(2,4-DIFLUORO-3-{2-[(3-HYDROXYPROPYL)AMINO]-8-METHYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-6-YL}PHENYL)PROPANE-1-SULFONAMIDE4e4xAL514 S536 F583 D594 F595 G596
29L2-{4-[(1E)-1-(HYDROXYIMINO)-2,3-DIHYDRO-1H-INDEN-5-YL]- 3-(PYRIDIN-4-YL)-1H-PYRAZOL-1-YL}ETHANOL4mnfAV471 L514 F583 D594
TV4N-(6-AMINO-5-BROMOPYRIDIN-3-YL)-2,6-DIFLUORO-3-[(PROPYLSULFONYL)AMINO]BENZAMIDE3tv4BV471 L514 F583 D594 F595 G596
RI84-AMINO-N-{2,6-DIFLUORO-3-[(PROPYLSULFONYL) AMINO]PHENYL}THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE4eheAV471 L514 F583 D594 F595 G596
RI84-AMINO-N-{2,6-DIFLUORO-3-[(PROPYLSULFONYL) AMINO]PHENYL}THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE4eheBV471 L514 F583 D594 F595 G596
RI9N-{2,4-DIFLUORO-3-[({6-[(2-HYDROXYETHYL) AMINO]PYRIMIDIN-4-YL}CARBAMOYL)AMINO]PHENYL}PROPANE-1- SULFONAMIDE4ehgAV471 L514 F583 D594 F595 G596
2VXN-{2,4-DIFLUORO-3-[METHYL(3-METHYL-4-OXO-3,4- DIHYDROQUINAZOLIN-6-YL)AMINO]PHENYL}PROPANE-1- SULFONAMIDE4pp7AV471 L514 F583 D594 F595 G596
P02N'-{3-[5-(2-AMINOPYRIMIDIN-4-YL)-2-TERT-BUTYL-1,3- THIAZOL-4-YL]-2-FLUOROPHENYL}-N-ETHYL-N-METHYLSULFURIC DIAMIDE4xv3AV471 L514 F583 D594 F595 G596
L1EN5-(3-(9H-PURIN-6-YL)PYRIDIN-2-YL)-N1-(4-CHLOROPHENYL)-6-METHYLISOQUINOLINE-1,5-DIAMINE3idpBV471 L514 F583 G593 D594 F595
0NF(2S)-N-[3-(2-AMINOPROPAN-2-YL)-5-(TRIFLUOROMETHYL)PHENYL]-7-[(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-4-YL)OXY]-1,2,3,4-TETRAHYDRONAPHTHALENE-2-CARBOXAMIDE3q96BV471 L514 F583 G593 D594 F595 A598
L1EN5-(3-(9H-PURIN-6-YL)PYRIDIN-2-YL)-N1-(4-CHLOROPHENYL)-6-METHYLISOQUINOLINE-1,5-DIAMINE3idpAV471 L514 G593 D594 F595
B961-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA4jvgBV471 L514 G593 D594 F595
B961-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA4jvgCV471 L514 G593 D594 F595
DFS2,6-DIFLUORO-N-(1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-3- [(PROPYLSULFONYL)AMINO]BENZAMIDE4mbjAV471 L514 G593 D594 F595 G596 L597
T1QN-(2,4-DIFLUORO-3-{2-[(3-HYDROXYPROPYL)AMINO]-8-METHYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-6-YL}PHENYL)PROPANE-1-SULFONAMIDE4e4xBV471 L514 S536 F583 D594 F595 G596


Top
Conservation information for LBS of BRAF
Multiple alignments for P15056 in multiple species
LBSAA sequence# speciesSpecies
A481WHGDVAVKMLN3Homo sapiens, Gallus gallus, Mus musculus
A481FFGTVAIKKLN1Caenorhabditis elegans
A481WHGPVAVKTLN1Drosophila melanogaster
A598GDFGLATVKSR3Homo sapiens, Gallus gallus, Mus musculus
A598GDFGLATVKTK1Caenorhabditis elegans
A598GDFGLATAKTR1Drosophila melanogaster
C532IVTQWCEGSSL4Homo sapiens, Drosophila melanogaster, Gallus gallus, Mus musculus
C532IITQWCEGSSL1Caenorhabditis elegans
D594TVKIGDFGLAT4Homo sapiens, Caenorhabditis elegans, Gallus gallus, Mus musculus
D594SVKIGDFGLAT1Drosophila melanogaster
E501QAFKNEVGVLR3Homo sapiens, Gallus gallus, Mus musculus
E501AAFKNEVAVLK1Caenorhabditis elegans
E501QAFKNEVAMLK1Drosophila melanogaster
E533VTQWCEGSSLY4Homo sapiens, Drosophila melanogaster, Gallus gallus, Mus musculus
E533ITQWCEGSSLY1Caenorhabditis elegans
F468IGSGSFGTVYK3Homo sapiens, Gallus gallus, Mus musculus
F468VGSGSFGTVYR1Caenorhabditis elegans
F468IGSGSFGTVYR1Drosophila melanogaster
F516VNILLFMGYST3Homo sapiens, Gallus gallus, Mus musculus
F516LNVLLFMGWVR1Caenorhabditis elegans
F516CNILLFMGCVS1Drosophila melanogaster
F583KSNNIFLHEDL4Homo sapiens, Drosophila melanogaster, Gallus gallus, Mus musculus
F583KTNNIFLMDDM1Caenorhabditis elegans
F595VKIGDFGLATV4Homo sapiens, Caenorhabditis elegans, Gallus gallus, Mus musculus
F595VKIGDFGLATA1Drosophila melanogaster
G464VGQRIGSGSFG3Homo sapiens, Gallus gallus, Mus musculus
G464IQYKVGSGSFG1Caenorhabditis elegans
G464IGPRIGSGSFG1Drosophila melanogaster
G466QRIGSGSFGTV3Homo sapiens, Gallus gallus, Mus musculus
G466YKVGSGSFGTV1Caenorhabditis elegans
G466PRIGSGSFGTV1Drosophila melanogaster
G534TQWCEGSSLYH3Homo sapiens, Gallus gallus, Mus musculus
G534TQWCEGSSLYR1Caenorhabditis elegans
G534TQWCEGSSLYK1Drosophila melanogaster
G593-TVKIGDFGLA3Homo sapiens, Gallus gallus, Mus musculus
G593STVKIGDFGLA1Caenorhabditis elegans
G593-SVKIGDFGLA1Drosophila melanogaster
G596KIGDFGLATVK4Homo sapiens, Caenorhabditis elegans, Gallus gallus, Mus musculus
G596KIGDFGLATAK1Drosophila melanogaster
H539GSSLYHHLHII3Homo sapiens, Gallus gallus, Mus musculus
H539GSSLYRHIHVQ1Caenorhabditis elegans
H539GSSLYKHVHVS1Drosophila melanogaster
H574AKSIIHRDLKS3Homo sapiens, Gallus gallus, Mus musculus
H574SKNIIHRDLKT1Caenorhabditis elegans
H574AKNIIHRDLKS1Drosophila melanogaster
I463TVGQRIGSGSF3Homo sapiens, Gallus gallus, Mus musculus
I463IIQYKVGSGSF1Caenorhabditis elegans
I463LIGPRIGSGSF1Drosophila melanogaster
I513TRHVNILLFMG3Homo sapiens, Gallus gallus, Mus musculus
I513TRHLNVLLFMG1Caenorhabditis elegans
I513TRHCNILLFMG1Drosophila melanogaster
I527KPQLAIVTQWC3Homo sapiens, Gallus gallus, Mus musculus
I527EPEIAIITQWC1Caenorhabditis elegans
I527KPSLAIVTQWC1Drosophila melanogaster
I543YHHLHIIETK-3Homo sapiens, Gallus gallus, Mus musculus
I543YRHIHVQEPRV1Caenorhabditis elegans
I543YKHVHVSETK-1Drosophila melanogaster
I572LHAKSIIHRDL3Homo sapiens, Gallus gallus, Mus musculus
I572LHSKNIIHRDL1Caenorhabditis elegans
I572LHAKNIIHRDL1Drosophila melanogaster
I592L-TVKIGDFGL3Homo sapiens, Gallus gallus, Mus musculus
I592MSTVKIGDFGL1Caenorhabditis elegans
I592L-SVKIGDFGL1Drosophila melanogaster
K483GDVAVKMLNVT3Homo sapiens, Gallus gallus, Mus musculus
K483GTVAIKKLNVV1Caenorhabditis elegans
K483GPVAVKTLNVK1Drosophila melanogaster
L505NEVGVLRKTRH3Homo sapiens, Gallus gallus, Mus musculus
L505NEVAVLKKTRH1Caenorhabditis elegans
L505NEVAMLKKTRH1Drosophila melanogaster
L514RHVNILLFMGY3Homo sapiens, Gallus gallus, Mus musculus
L514RHLNVLLFMGW1Caenorhabditis elegans
L514RHCNILLFMGC1Drosophila melanogaster
L567QGMDYLHAKSI3Homo sapiens, Gallus gallus, Mus musculus
L567LGMNYLHSKNI1Caenorhabditis elegans
L567QGMDYLHAKNI1Drosophila melanogaster
L597IGDFGLATVKS3Homo sapiens, Gallus gallus, Mus musculus
L597IGDFGLATVKT1Caenorhabditis elegans
L597IGDFGLATAKT1Drosophila melanogaster
N580RDLKSNNIFLH4Homo sapiens, Drosophila melanogaster, Gallus gallus, Mus musculus
N580RDLKTNNIFLM1Caenorhabditis elegans
N581DLKSNNIFLHE4Homo sapiens, Drosophila melanogaster, Gallus gallus, Mus musculus
N581DLKTNNIFLMD1Caenorhabditis elegans
Q530LAIVTQWCEGS4Homo sapiens, Drosophila melanogaster, Gallus gallus, Mus musculus
Q530IAIITQWCEGS1Caenorhabditis elegans
S465GQRIGSGSFGT3Homo sapiens, Gallus gallus, Mus musculus
S465QYKVGSGSFGT1Caenorhabditis elegans
S465GPRIGSGSFGT1Drosophila melanogaster
S535QWCEGSSLYHH3Homo sapiens, Gallus gallus, Mus musculus
S535QWCEGSSLYRH1Caenorhabditis elegans
S535QWCEGSSLYKH1Drosophila melanogaster
S536WCEGSSLYHHL3Homo sapiens, Gallus gallus, Mus musculus
S536WCEGSSLYRHI1Caenorhabditis elegans
S536WCEGSSLYKHV1Drosophila melanogaster
T508GVLRKTRHVNI3Homo sapiens, Gallus gallus, Mus musculus
T508AVLKKTRHLNV1Caenorhabditis elegans
T508AMLKKTRHCNI1Drosophila melanogaster
T529QLAIVTQWCEG3Homo sapiens, Gallus gallus, Mus musculus
T529EIAIITQWCEG1Caenorhabditis elegans
T529SLAIVTQWCEG1Drosophila melanogaster
V471GSFGTVYKGKW3Homo sapiens, Gallus gallus, Mus musculus
V471GSFGTVYRGEF1Caenorhabditis elegans
V471GSFGTVYRAHW1Drosophila melanogaster
V482HGDVAVKMLNV3Homo sapiens, Gallus gallus, Mus musculus
V482FGTVAIKKLNV1Caenorhabditis elegans
V482HGPVAVKTLNV1Drosophila melanogaster
V504KNEVGVLRKTR3Homo sapiens, Gallus gallus, Mus musculus
V504KNEVAVLKKTR1Caenorhabditis elegans
V504KNEVAMLKKTR1Drosophila melanogaster
W531AIVTQWCEGSS4Homo sapiens, Drosophila melanogaster, Gallus gallus, Mus musculus
W531AIITQWCEGSS1Caenorhabditis elegans
Y538EGSSLYHHLHI3Homo sapiens, Gallus gallus, Mus musculus
Y538EGSSLYRHIHV1Caenorhabditis elegans
Y538EGSSLYKHVHV1Drosophila melanogaster


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas